CalciMedica, Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica, Inc. (NASDAQ:CALC) was the target of a large drop in short interest in April. As of April 15th, there was short interest totalling 33,600 shares, a drop of 9.7% from the March 31st total of 37,200 shares. Based on an average daily volume of 23,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 0.7% of the shares of the stock are sold short.

CalciMedica Stock Performance

CALC stock traded down $0.20 during mid-day trading on Monday, reaching $5.25. The company had a trading volume of 15,627 shares, compared to its average volume of 21,203. CalciMedica has a fifty-two week low of $1.75 and a fifty-two week high of $8.59. The company has a market capitalization of $56.39 million, a price-to-earnings ratio of -0.20 and a beta of 1.61. The firm has a fifty day simple moving average of $4.33 and a 200 day simple moving average of $3.88.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.77. As a group, analysts predict that CalciMedica will post -2.04 earnings per share for the current year.

Analyst Ratings Changes

CALC has been the subject of several recent analyst reports. Oppenheimer reissued an “outperform” rating and set a $14.00 target price on shares of CalciMedica in a research note on Monday, April 1st. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of CalciMedica in a research report on Monday, April 1st. Finally, Jonestrading assumed coverage on shares of CalciMedica in a research report on Friday, February 16th. They issued a “buy” rating and a $22.00 target price on the stock.

Hedge Funds Weigh In On CalciMedica

Hedge funds have recently added to or reduced their stakes in the stock. Hudson Bay Capital Management LP acquired a new stake in shares of CalciMedica during the third quarter worth about $432,000. BML Capital Management LLC grew its stake in CalciMedica by 10.3% during the 1st quarter. BML Capital Management LLC now owns 160,424 shares of the company’s stock worth $667,000 after buying an additional 15,000 shares during the last quarter. Finally, Meritage Portfolio Management increased its position in CalciMedica by 360.0% during the fourth quarter. Meritage Portfolio Management now owns 46,000 shares of the company’s stock worth $132,000 after buying an additional 36,000 shares during the period.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases.